

ARTICLE



Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study

Hussein Kadhem Al-Hakeim¹, Haneen Tahseen Al-Rubaye², Dhurgham Shihab Al-Hadrawi³, Abbas F. Almulla^{4,5} and Michael Maes^{5,6,7}✉

© The Author(s), under exclusive licence to Springer Nature Limited 2022

The immune-inflammatory response during the acute phase of COVID-19, as assessed using peak body temperature (PBT) and peripheral oxygen saturation (SpO₂), predicts the severity of chronic fatigue, depression and anxiety symptoms 3–4 months later. The present study was performed to examine the effects of SpO₂ and PBT during acute infection on immune, oxidative and nitrosative stress (IO&NS) pathways and neuropsychiatric symptoms of Long COVID. This study assayed SpO₂ and PBT during acute COVID-19, and C-reactive protein (CRP), malondialdehyde (MDA), protein carbonyls (PCs), myeloperoxidase (MPO), nitric oxide (NO), zinc, and glutathione peroxidase (Gpx) in 120 Long COVID individuals and 36 controls. Cluster analysis showed that 31.7% of the Long COVID patients had severe abnormalities in SpO₂, body temperature, increased oxidative toxicity (OSTOX) and lowered antioxidant defenses (ANTIOX), and increased total Hamilton Depression (HAMD) and Anxiety (HAMA) and Fibromyalgia-Fatigue (FF) scores. Around 60% of the variance in the neuropsychiatric symptoms of Long COVID (a factor extracted from HAMD, HAMA and FF scores) was explained by OSTOX/ANTIOX ratio, PBT and SpO₂. Increased PBT predicted increased CRP and lowered ANTIOX and zinc levels, while lowered SpO₂ predicted lowered Gpx and increased NO production. Lowered SpO₂ strongly predicts OSTOX/ANTIOX during Long COVID. In conclusion, the impact of acute COVID-19 on the symptoms of Long COVID is partly mediated by OSTOX/ANTIOX, especially lowered Gpx and zinc, increased MPO and NO production and lipid peroxidation-associated aldehyde formation. The results suggest that post-viral somatic and mental symptoms have a neuroimmune and neuro-oxidative origin.

Molecular Psychiatry; <https://doi.org/10.1038/s41380-022-01836-9>

INTRODUCTION

Patients who have recovered from SARS-CoV-2 infection and have been discharged from the hospital may experience symptoms for much longer than expected, a condition known as “Long COVID.” [1–6]. Numerous other terms for post-COVID symptoms have been suggested, including post-acute COVID, protracted COVID, chronic post-COVID, and Long Haul COVID [7, 8]. The most often used definition is: symptoms persisting for more than 3 months from the onset of acute COVID-19 [9, 10]. Extended symptoms have been classified as probably infection-related (up to 4–5 weeks), acute post-COVID symptoms (weeks 5–12), prolonged post-COVID symptoms (weeks 12–24), and chronic post-COVID symptoms (more than 24 weeks) [7].

Following the acute phase of COVID-19, the presence of more than one symptom is quite prevalent, occurring in 74% [11, 12] to 87.4% of all infected patients [12]. Initially, patient concerns were

dismissed as mental health problems, including worry or stress [13], but later it became clear that people who suffer from long-term COVID have a wide range of physical and mental symptoms [14–16]. Among the various symptoms associated with Long COVID, the most frequently reported symptoms are fatigue and dyspnoea [9, 11, 17, 18], post-traumatic stress symptoms [19, 20], concentration and memory problems [21, 22], and anxiety and depression [4, 23]. Within 6 months after the first COVID-19 symptom, almost a third of COVID-19 survivors had a neuropsychiatric diagnosis such as insomnia, anxiety and depression [24].

Recently, we reported that not only the acute infectious phase [25] but also Long COVID [26] is characterized by concurrent elevations in depression (depressed mood, feelings of guilt, suicidal ideation, loss of interest), anxiety (anxious mood, tension, fears, anxiety behavior at interview), chronic fatigue and somatic symptoms including autonomic and gastrointestinal (GIS)

¹Department of Chemistry, College of Science, University of Kufa, Kufa, Iraq. ²College of Medical Laboratory Techniques, Imam Ja'afar Al-Sadiq University, Najaf, Iraq. ³Al-Najaf Center for Cardiac Surgery and Transcatheter Therapy, Najaf, Iraq. ⁴Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.

⁵Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. ⁶Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria. ⁷Deakin University, IMPACT, the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.

✉email: dr.michaelmaes@hotmail.com

Received: 30 April 2022 Revised: 1 October 2022 Accepted: 10 October 2022

Published online: 24 October 2022

symptoms, malaise and muscle pain. In addition, in both the acute phase and Long COVID, a single latent vector could be derived from these somatic and affective symptoms, demonstrating that these symptom profiles are the expression of a shared core, namely the acute COVID-19 and Long COVID neuropsychiatric symptoms [25, 26].

We reported that in acute COVID-19, the neuropsychiatric symptoms were largely predicted by a latent factor derived from indicators of increased proinflammatory and immunoregulatory cytokines, chest computerized tomography scan abnormalities (CCTAs), including ground-glass opacities, crazy patterns and consolidation and lower oxygen saturation in peripheral blood (SpO₂) [25]. Importantly, lowered SpO₂ and increased peak body temperature (PBT) during the acute phase of illness largely predict the severity of the neuropsychiatric symptoms of Long COVID [26]. Both lowered SpO₂ [26] and increased PBT [27] are indicators of the severity of the immune-inflammatory response of acute COVID-19, and both predict critical disease and mortality [27, 28]. Therefore, our findings indicate that the infectious-immune-inflammatory pathways during the acute phase of illness [29] largely predict the symptom core of Long COVID [26]. Nevertheless, there are no data on whether the biomarkers underpinning Long COVID are caused by the inflammatory responses during the acute phase.

Activated immune-inflammatory and oxidative and nitrosative stress (IO&NS) pathways may underpin the somatic and mental symptoms of Long COVID because chronic fatigue syndrome, major depression and generalized anxiety disorder (GAD) are characterized by activated IO&NS pathways. Thus, these disorders are accompanied by (a) signs of a mild inflammatory response as indicated by increased levels of C-reactive protein (CRP); (b) oxidative stress including increased activity of pro-oxidative enzymes including myeloperoxidase (MPO) and oxidative damage as indicated by elevated production of malondialdehyde (MDA), protein carbonyls (PCs) and advanced protein oxidation products (AOPP); (c) increased nitrosative stress as indicated by increased levels of nitric oxide (NO) metabolites and IgM directed to NO (nitroso) neoepitope adducts; and (d) indicators of lowered total antioxidant capacity (TAC) of plasma, glutathione peroxidase (Gpx) and zinc levels [30–34]. In chronic fatigue syndrome, depression and GAD, the neurotoxicity theories conceptualize that the effects of neuro-oxidative stress toxicity (OSTOX) coupled with lowered antioxidant (ANTIOX) defenses cause increased neurotoxicity leading to somatic and affective symptoms [30, 31]. This is supported by translational data indicating that blocking nitro-oxidative stress, inflammatory and neurotoxic pathways with selective antioxidative compounds may alleviate depressive-, anxiety-, and chronic fatigue-like behaviors [25, 26, 30, 35–40]. Moreover, in humans, treatment with selected antioxidants improves depression, anxiety and chronic fatigue symptoms [41–44].

Likewise, SARS-Cov-2 infection and acute COVID-19 are accompanied by an inflammatory response [29], increased MPO activity [45], indicators of oxidative damage [46–48] and increased NO production including increased levels of nitrotyrosine [49], and lowered antioxidant defenses (ANTIOX) as indicated by reduced TAC levels [45, 49], Gpx [50], and zinc [51]. Nevertheless, there are no data on whether the effects of the immune-inflammatory processes during acute infection (as indicated by lowered SpO₂ and increased body temperature) on the neuropsychiatric symptoms are mediated by activated immune and O&NS (IO&NS) pathways.

Hence, the present study was performed to delineate whether the effects of SpO₂ and PBT on the neuropsychiatric symptoms of Long COVID are mediated by IO&NS pathways, including CRP, the OSTOX/ANTIOX ratio and its indicators (MDA, AOPP, carbonyl proteins, NOx, nitrotyrosine, TAC, Gpx or zinc). In addition, the present work employs the precision medicine approach [51] to define a Long COVID model which links the acute inflammation of COVID-19 with IO&NS pathways and the neuropsychiatric

symptoms 3–4 months later. Moreover, we intend to construct an endophenotype class [34] that integrates all those biomarkers with the neuropsychiatric symptoms of Long-COVID. These findings are necessary to comprehend the biology of Long COVID and post-viral symptoms in general and may aid in predicting who will develop chronic fatigue syndrome and affective symptoms as a result of COVID-19 and viral infections in general.

SUBJECTS AND METHODS

Subjects

We employed both a case-control research design (to explore differences between controls and Long COVID) and a retrospective cohort study design (to examine the effects of acute-phase biomarkers on Long COVID symptoms) in the current investigation. We recruited 120 patients in the last 3 months of 2021 who had at least two symptoms consistent with Long COVID and had previously been diagnosed and treated for acute COVID-19 infection. The patients were diagnosed using the WHO criteria of post-COVID (long COVID) [52], namely: (a) individuals having a history of proven SARS-CoV-2 infection, (b) symptoms persisted beyond the acute phase of illness or manifested during recovery from acute COVID-19 infection, (c) symptoms lasted at least 2 months and are present 3–4 months after the onset of COVID-19, and (d) patients suffer from at least two symptoms that impair daily functioning including fatigue, memory or concentration problems, shortness of breath, chest pain, persistent cough, difficulty speaking, muscle aches, loss of smell or taste, affective symptoms, cognitive impairment, or fever [52].

During the acute phase of the illness, all patients had been admitted to one of the official quarantine facilities in Al-Najaf city specialized in the treatment of acute COVID-19, including Al-Sader Medical City of Najaf, Al-Hakeem General Hospital, Al-Zahraa Teaching Hospital for Maternity and Pediatrics, Imam Sajjad Hospital, Hassan Halos Al-Hatmy Hospital for Transmitted Diseases, Middle Euphrates Center for Cancer, and Al-Najaf. Senior doctors and virologists made the diagnosis of SARS-CoV-2 infection and acute COVID-19 based on (a) presence of an acute respiratory syndrome and the disease's standard symptoms of fever, breathing difficulties, coughing, and loss of smell and taste; (b) positive reverse transcription real-time polymerase chain reaction findings (rRT-PCR); and (c) positive IgM directed to SARS-CoV-2. All patients showed, upon recovery from the acute phase, a negative rRT-PCR result.

We selected 36 controls from the same catchment area, who were either staff members or their family or friends. In addition, we included controls who tested negative for rRT-PCR and exhibited no clinical indications of acute infection, such as dry cough, sore throat, shortness of breath, lack of appetite, flu-like symptoms, fever, night sweats, or chills. Nevertheless, we selected the controls so that about one-third of them had distress or adjustment symptoms as a result of lockdowns and social isolation to account for their confounding effects, which are also seen in Long COVID patients. Thus, one-third of the controls showed Hamilton Depression Rating Scale (HAM-D) [53] values between 7 and 12. A senior psychiatrist reviewed the lifetime history of neuropsychiatric disorders based on the clinical anamnesis and patient records. COVID patients and controls were excluded if they had a lifetime history of psychiatric axis-1 disorders, including major affective disorders such as major depression and bipolar disorder, dysthymia, GAD and panic disorder, schizo-affective disorder, schizophrenia, psycho-organic syndrome, and substance use disorders, except tobacco use disorder (TUD). Moreover, we excluded patients and controls who suffered from neurodegenerative and neuroinflammatory disorders, such as chronic fatigue syndrome [54], Parkinson's or Alzheimer's disease, multiple sclerosis, stroke, or systemic (auto)immune diseases such as diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease and scleroderma, and liver and renal disease. In addition, pregnant and breastfeeding women were omitted from this study.

All controls and patients, or their parents/legal guardians, gave written informed permission before participation in the research. The research was approved by the University of Kufa's institutional ethics board (8241/2021) and the Najaf Health Directorate-Training and Human Development Center (Document No.18378/ 2021). The study was conducted following Iraqi and international ethical and privacy laws, including the World Medical Association's Declaration of Helsinki, The Belmont Report, the CIOMS Guideline, and the International Conference on Harmonization of Good Clinical Practice; our institutional review board adheres to the International Guidelines for Human Research Safety (ICH-GCP).

Clinical measurements

A senior psychiatrist used a semi-structured interview to collect socio-demographic and clinical data from controls and Long COVID patients 3–4 months after the acute infectious phase of COVID-19 (mean \pm SD duration of illness was 14.68 ± 5.31 weeks). Three to four months after the onset of acute COVID-19, this senior psychiatrist assessed the following rating scales: (a) the 12-item Fibro-Fatigue (FF) scale to measure Chronic fatigue and fibromyalgia symptoms [55]; (b) the HAMD to assess the severity of depression [53]; and (c) the Hamilton Anxiety Rating Scale (HAMA) [56] to assess the severity of anxiety. However, all three scales encompass both mental (affective) and somatic symptoms; consequently, utilizing the total scores would produce equivocal findings about affective symptoms due to the influence of somatic symptoms on the total scores. As previously explained, we have calculated composites representing affective symptoms of the HAMA and HAMD and somatic symptoms of the HAMD, HAMA, and FF scores [25]. Thus, two HAMD subdomain scores were calculated: (a) depressive HAMD symptoms as the sum of sad mood + feelings of guilt + suicidal thoughts + loss of interest; and (b) somatic HAMD symptoms as the sum of somatic anxiety + GIS anxiety + genitourinary anxiety + hypochondriasis. Two HAMA subdomain scores were calculated: (a) anxiety HAMA symptoms, which were defined as anxious mood + tension + fears + anxiety behavior during the interview; and (b) somatic HAMA symptoms, defined as somatic sensory + cardiovascular + GIS + genitourinary + autonomic symptoms (respiratory symptoms were not included in the sum). We calculated a single somatic FF subdomain score as: muscular pain + muscle tension + fatigue + autonomic symptoms + GIS symptoms + headache + a flu-like malaise (thus excluding the cognitive and affective symptoms). We examined the psychometric properties of the first factor extracted from the somatic FF, HAMA, and HAMD scores as well as the affective HAMD and HAMA scores in order to determine if it is possible to construct a latent vector score that adequately reflects the overall neuropsychiatric symptoms (combining somatic and mental symptoms) [25, 26]. This is significant because, if a single valid vector can be identified (see below for criteria), it demonstrates that somatic and affective symptoms have a common core and, hence, a shared pathophysiology [25]. In addition, we constructed z-unit-based composite scores indicating autonomic symptoms, sleep problems, fatigue, GIS symptoms, and cognitive symptoms using all relevant HAMD, HAMA, and FF items (z transformed). TUD was diagnosed using DSM-5 criteria. We determined the body mass index (BMI) by dividing the body weight in kilograms by the squared height in meters.

Assays

Fasting blood samples were taken in the early morning between 7.30 and 9.00 a.m. after awakening and before having breakfast. Five milliliters of venous blood samples were drawn and transferred into clean plain tubes. Hemolyzed samples were rejected. After 10 min, the clotted blood samples were centrifuged for 5 min at 3000 rpm, and then serum was separated and transported into three new Eppendorf tubes until assay. Serum Gpx, NOx, MPO, MDA, AOPP, TAC, nitrotyrosine, and PCs were measured using ELISA kits supplied by Nanjing Pars Biochem Co., Ltd. (Nanjing, China). All kits were based on a sandwich technique and showed an inter-assay CV of <10%. Zinc in serum was measured spectrophotometrically using a ready for use kit supplied by Agappe Diagnostics Ltd., Cham, Switzerland. Consequently, we computed three composite scores: (a) oxidative stress toxicity (OSTOX) as the sum of z MDA + z AOPP + z carbonyl proteins + z MPO + z NOx + z nitrotyrosine; (b) ANTIOX as z TAC + z Gpx + z zinc; and (c) the OSTOX/ANTIOX ratio as z OSTOX - z ANTIOX. The laboratory operators were blinded to the clinical data.

A well-trained paramedical specialist measured SpO2 using an electronic oximeter supplied by Shenzhen Jumper Medical Equipment Co. Ltd., and a digital thermometer was used to assess body temperature (sublingual until the beep). We collected these indicators from patient records and analyzed the lowest SpO2 and PBT values recorded during the acute phase of illness. We created a new indicator based on these two evaluations that represents decreased SpO2 and increased PBT as the z transformation of the latter (z body temperature) - z SpO2 (dubbed the "TO2 index"). We recorded the immunizations received by each participant, namely AstraZeneca, Pfizer, or Sinopharm.

Statistics

Analysis of variance was performed to determine if there were variations in scale variables across groups, and analysis of contingency tables or Fisher's Exact Probability test were employed to determine connections between

nominal variables. We used Pearson's product-moment correlation coefficients to examine relationships between ONS biomarkers and SpO2, PBT, and clinical assessments. We employed a univariate general linear model (GLM) analysis to characterize the associations between classifications and biomarkers while accounting for confounding factors such as TUD, sex, age, BMI, and education. Equality of variance between study groups was tested using the Levene test. In addition, we obtained model-generated estimated marginal means (SE) values and used protected pairwise comparisons between group means using Fisher's least significant difference. Multiple comparisons were examined using a p correction for false discovery rate (FDR) [57]. Multiple regression analysis was used to determine the important IO&NS biomarkers or cofounders that predict somatic and affective measures. We used an automated stepwise technique with a 0.05 p value to enter and $p = 0.06$ to remove. We calculated the standardized beta coefficients for each significant explanatory variable using t statistics with exact p value, as well as the model F statistics and total variance explained (R^2). In addition, we examined multicollinearity using the variance inflation factor and tolerance. We checked for heteroskedasticity using the White and modified Breusch-Pagan tests, and where necessary, we generated parameter estimates with robust errors. Associations between biomarkers and clinical data were assessed in an unrestricted study group consisting of patients and controls combined (the primary analyses). We also assessed the associations in the restricted group of Long COVID patients only (the secondary analyses). The tests were two-tailed, and statistical significance was defined as a p value of 0.05. Using an effect size of 0.23, a p value of 0.05, a power of 0.8, and three groups with up to five variables in an analysis of variance, the sample size should be around 151 participants (estimated using GPower 3.1). As a result, we enrolled 156 individuals, 36 controls and 120 Long COVID participants.

The precision medicine approach

By integrating biomarker and clinical data, we hoped to create endophenotype classes for Long COVID patients (using cluster analysis) and novel pathway phenotypes (using factor analysis). We conducted two-step cluster analyses on categorical (e.g., diagnosis) and scale variables (e.g., all biomarkers) to define new meaningful clusters of Long COVID patients. When the silhouette measure of cohesiveness and separation was more than 0.4, the cluster solution was deemed satisfactory. We conducted exploratory factor analysis (unweighted least-squares extraction, 25 iterations for convergence) and assessed factorability using the Kaiser-Meier-Olkin (KMO) sample adequacy metric (adequate when >0.7). In addition, when all loadings on the first factor were >0.6, the variance explained by the first factor was >50.0%, and the Cronbach alpha on the variables was >0.7; the first factor was considered a validated latent construct underlying the variables. Canonical correlation analysis (CCA) was used to investigate the associations between two sets of variables, with symptoms 3–4 months following the acute phase serving as the dependent variable set and both biomarkers of the acute and Long COVID phases as the explanatory variable set. We calculated the variance explained by the canonical variables in both sets, and we accept the canonical sets as an overall measure of the underlying construct when the explained variance is >0.50 and all canonical loadings are >0.5. Finally, we also compute the variance explained in the dependent clinical set by the biomarker set. All statistical analyses were conducted using IBM SPSS Windows, version 28.

Smart PLS analysis [58] was utilized to investigate the causal links between the lowest SpO2 and PBT in the acute phase and the neuropsychiatric symptoms in Long COVID, whereby the effects of SpO2 and temperature are mediated by IO&NS biomarkers. All input variables were entered as single indicators, while the output variable was a latent vector extracted from somatic FF, HAMD and HAMA, and affective HAMD and HAMA scores. Complete PLS analysis was performed only when the inner and outer models met predefined quality criteria, namely: (a) the output LV has high composite reliability >0.7, Cronbach's alpha >0.7, and rho A >0.8 with an average variance extracted (AVE) >0.5, (b) all LV loadings are >0.6 at $p < 0.001$, (c) the model fit is <0.08 in terms of standardized root mean squared residual (SRMR), (d) confirmatory tetrad analysis shows that the LV was not incorrectly specified as a reflective model, (e) blindfolding shows that the construct's cross-validated redundancy is adequate, and (f) the model's prediction ability as evaluated using PLSpredict is adequate. If the model quality data are adequate, we perform a complete PLS pathway analysis using 5000 bootstrap samples and compute the path coefficients with exact p value, as well as specific and total indirect (mediated) effects and total effects.

Table 1. Socio-demographic and biomarkers data of controls and Long COVID (LC) patients divided into two groups one with highly increased body temperature, lowered SpO2 and high nitro-oxidative stress (LC + O&NS) versus another group with fewer changes in these biomarkers (LC).

| Variables | Controls (n = 36) ^A | Cluster 1 or LC (n = 67) ^B | Cluster 2: LC + O&NS (n = 51) ^C | F/ψ/χ ² | df | p |
|---|--------------------------------|---------------------------------------|--|--------------------|-------|--------|
| Age (years) | 30.9 ± 8.3 | 29.3 ± 7.2 | 33.1 ± 8.6 | 3.32 | 2/151 | 0.039 |
| BMI (kg/m ²) | 26.34 ± 3.64 | 25.60 ± 3.97 | 26.65 ± 6.20 | 0.72 | 2/146 | 0.487 |
| Sex (Female/Male) | 6/30 | 25/42 | 8/43 | 9.02 | 2 | 0.012 |
| Education (years) | 15.8 ± 1.2 ^C | 15.6 ± 1.6 ^C | 15.5 ± 1.8 ^{A,B} | 0.37 | 2/151 | 0.689 |
| Single/married | 22/14 | 34/33 | 15/36 | 9.56 | 2 | 0.008 |
| TUD (No/Yes) | 20/16 | 45/22 | 36/15 | 2.24 | 2 | 0.321 |
| Residency (Urban/Rural) | 7/29 | 7/60 | 12/39 | 3.75 | 2 | 0.166 |
| Employment (No/Yes) | 36 | 67 | 51 | – | – | – |
| Vaccination (A/Pf/S) | 11/14/11 | 23/30/14 | 20/19/12 | 1.83 | 4 | 0.768 |
| Duration of Disease (weeks) | – | 13.8 ± 3.7 ^C | 15.8 ± 6.8 ^B | 4.16 | 1/116 | 0.044 |
| Peak body temperature (°C) | 36.5 ± 0.1 ^{B,C} | 38.8 ± 0.1 ^{A,C} | 39.3 ± 0.1 ^{A,B} | 163.99 | 2/142 | <0.001 |
| Lowest SpO2 (%) | 96.6 ± 0.6 ^{B,C} | 92.3 ± 0.4 ^{A,C} | 87.5 ± 0.5 ^{A,B} | 70.06 | 2/142 | <0.001 |
| zTO2 index (z scores) | –1.340 ± 0.091 ^{B,C} | 0.143 ± 0.070 ^{A,C} | 0.862 ± 0.079 ^{A,B} | 170.24 | 2/142 | <0.001 |
| Gpx (ng/ml) | 23.46 ± 0.97 ^{B,C} | 21.57 ± 0.75 ^{A,C} | 17.97 ± 0.84 ^{A,B} | 9.84 | 2/142 | <0.001 |
| NO (uM) | 20.81 ± 1.47 ^C | 18.95 ± 1.13 ^C | 28.19 ± 1.27 ^{A,B} | 14.99 | 2/142 | <0.001 |
| Protein carbonyl (ng/ml) | 11.38 ± 1.15 ^C | 10.73 ± 0.89 ^C | 14.43 ± 1.00 ^{A,B} | 3.97 | 2/142 | 0.021 |
| MPO (ng/ml) | 12.87 ± 0.82 ^C | 11.25 ± 0.63 ^C | 15.84 ± 0.71 ^{A,B} | 11.32 | 2/142 | <0.001 |
| MDA (nM) | 1406.9 ± 97.9 ^C | 1432.9 ± 75.5 ^C | 1843.0 ± 84.6 ^{A,B} | 8.02 | 2/142 | <0.001 |
| AOPP (uM) | 4.84 ± 0.38 | 5.27 ± 0.29 | 5.87 ± 0.33 | 2.19 | 2/142 | 0.116 |
| TAC (U/ml) | 6.23 ± 0.48 | 5.23 ± 0.37 | 5.01 ± 0.41 | 2.09 | 2/142 | 0.128 |
| Nitrotyrosine (nM) | 33.44 ± 3.20 | 34.79 ± 2.46 | 32.72 ± 2.76 | 0.16 | 2/142 | 0.865 |
| Zinc (ppm) | 0.785 ± 0.034 ^C | 0.772 ± 0.026 ^C | 0.657 ± 0.030 ^{A,B} | 5.37 | 2/142 | 0.006 |
| OSTOX (z scores) | –0.357 ± 0.131 ^C | –0.512 ± 0.101 ^C | 0.882 ± 0.113 ^{A,B} | 45.19 | 2/142 | <0.001 |
| ANTIOX (z scores) | 0.521 ± 0.151 ^{B,C} | 0.107 ± 0.116 ^{A,C} | –0.580 ± 0.130 ^{A,B} | 16.17 | 2/142 | <0.001 |
| OSTOX / ANTIOX (z scores) | –0.575 ± 0.129 ^A | –0.406 ± 0.100 ^A | 0.957 ± 0.113 ^{A,B} | 53.62 | 2/142 | <0.001 |
| CRP (mg/L) | 5.42 (0.70) ^{B,C} | 7.83 (0.55) ^A | 9.11 (0.61) ^A | 7.96 | 2/140 | <0.001 |
| Enoxaparin sodium (No/Yes) ^a | | 61/6 | 38/13 | 5.86 | 1 | 0.015 |
| Dexamethasone (No/Yes) ^a | | 54/13 | 27/24 | 10.29 | 1 | 0.001 |
| Ceftriaxone (No/Yes) ^a | | 51/16 | 34/17 | 1.28 | 1 | 0.257 |
| Azithromycine (No/Yes) ^a | | 31/36 | 25/26 | 0.09 | 1 | 0.767 |
| Bromhexine (No/Yes) ^a | | 50/17 | 26/25 | 7.06 | 1 | 0.008 |
| Levofloxacin (No/Yes) ^a | | 61/6 | 41/10 | 2.80 | 1 | 0.094 |
| Antidepressants (No/Yes) ^b | | 55/12 | 35/16 | 2.90 | 1 | 0.089 |
| Chlordiazepoxide (No/Yes) ^b | | 65/2 | 45/6 | FEPT | 1 | 0.059 |
| Propranolol (No/Yes) ^b | | 63/4 | 49/2 | 0.25 | 1 | 0.616 |

All results are shown as mean (SD) or as ratios. ^{A,B,C} Posthoc comparisons among group means. FEPT: Fisher's Exact Probability test.

BMI: body mass index, TUD: tobacco-use disorder, Vaccination A1,Pf,S: vaccination type either AstraZeneca (A), Pfizer-BioNTech (Pf), or Sinopharm (S).

zTO2 composite score reflecting combined aberrations in body temperature and SpO2, Gpx glutathione peroxidase, NOx nitric oxide, MPO myeloperoxidase, MDA malondialdehyde, AOPP advanced oxidation protein products, TAC total antioxidant capacity.

^aTreatments during the acute phase of COVID-19.

^bTreatments in Long-COVID.

RESULTS

Construction of an endophenotype class based on all biomarkers

To discover new endophenotype classes of Long COVID patients, we used a two-step cluster analysis with the diagnosis (Long COVID versus controls as a category) and the acute COVID-19 biomarkers SpO2 and body temperature and Long COVID biomarkers OSTOX, ANTIOX, OSTOX/ANTIOX and CRP as continuous variables. Nevertheless, the solution without CRP was much better, and, therefore, CRP was deleted from the model. We found a three-group model with an adequate measure of cohesion and separation of 0.57, namely controls ($n = 36$) and two patient clusters comprising 67 (cluster 1) and 51 (cluster 2) patients, respectively. Table 1 shows the socio-demographic and biomarker data of the three clusters. Cluster 2 patients showed lower SpO2, zinc, Gpx and ANTIOX levels and higher body temperature,

OSTOX, OSTOX/ANTIOX, NOx, MPO, MDA and protein carbonyl levels as compared with cluster 1 patients. As such, the Long COVID group is divided into two clusters, one (cluster 2) with highly activated O&NS pathways (LC + O&NS) and one with less severe aberrations (LC). The LC group was differentiated from controls by increased body temperature and CRP and lowered SpO2, Gpx and ANTIOX values. There were significant differences between both Long COVID classes in Gpx ($F = 12.79$, $df = 1/116$, $p < 0.001$), NO ($F = 37.98$, $df = 1/116$, $p < 0.001$), PCs ($F = 8.89$, $df = 1/116$, $p = 0.003$), MPO ($F = 23.72$, $df = 1/116$, $p < 0.001$), MDA ($F = 9.88$, $df = 1/116$, $p = 0.002$), zinc ($F = 5.79$, $df = 1/116$, $p = 0.018$), OSTOX ($F = 106.16$, $df = 1/116$, $p < 0.001$), ANTIOX ($F = 16.96$, $df = 1/116$, $p < 0.001$), OSTOX/ANTIOX ($F = 113.10$, $df = 1/116$, $p < 0.001$), and CRP ($F = 7.62$, $df = 1/116$, $p = 0.007$), whilst AOPP ($F = 2.74$, $df = 1/116$, $p = 0.101$), TAC ($F = 1.10$, $df = 1/116$, $p = 0.296$), and nitrotyrosine ($F = 0.73$, $df = 1/116$, $p = 0.396$)

Table 2. Estimated marginal mean scores of clinical ratings in controls and Long COVID patients divided into two groups one with highly increased body temperature, lowered SpO2 and high nitro-oxidative stress (LC + O&NS) versus another group with fewer changes in these biomarkers (LC).

| Biomarkerse | Controls ^A | Cluster 1 or LC (n = 67) | Cluster 2: LC + O&NS (n = 51) | F | df | p |
|--------------------------------------|-------------------------------|------------------------------|-------------------------------|-------|-------|---------|
| Total HAMD | 6.01 (0.82) ^{B,C} | 15.24 (0.61) ^{A,C} | 20.17 (0.70) ^{A,B} | 88.39 | 2/147 | <0.0001 |
| Total HAMA | 7.65 (1.27) ^{B,C} | 17.78 (0.94) ^{A,C} | 23.72 (1.08) ^{A,B} | 46.95 | 2/147 | <0.0001 |
| Total FF | 7.11 (1.66) ^{B,C} | 23.30 (1.24) ^{A,C} | 31.06 (1.42) ^{A,B} | 61.66 | 2/147 | <0.0001 |
| Depression HAMD | 1.65 (0.29) ^{B,C} | 4.22 (0.21) ^{A,C} | 5.85 (0.25) ^{A,B} | 62.39 | 2/147 | <0.0001 |
| Somatic HAMD | 1.65 (0.34) ^{B,C} | 4.34 (0.26) ^{A,C} | 5.92 (0.29) ^{A,B} | 44.95 | 2/147 | <0.0001 |
| Anxiety HAMA | 1.65 (0.33) ^{B,C} | 3.38 (0.25) ^A | 4.06 (0.28) ^A | 16.26 | 2/147 | <0.0001 |
| Somatic HAMA | 3.17 (0.61) ^{B,C} | 7.86 (0.46) ^{A,C} | 11.52 (0.53) ^{A,B} | 53.57 | 2/147 | <0.0001 |
| Somatic FF | 4.61 (1.01) ^{B,C} | 15.69 (0.76) ^{A,C} | 20.71 (0.87) ^{A,B} | 74.64 | 2/147 | <0.0001 |
| Neuropsychiatric symptoms (z score) | -1.167 (0.118) ^{B,C} | 0.043 (0.088) ^{A,C} | 0.766 (0.101) ^{A,B} | 77.78 | 2/147 | <0.001 |
| Autonomic symptoms (z score) | -1.157 (0.122) ^{B,C} | 0.139 (0.091) ^{A,C} | 0.623 (0.104) ^{A,B} | 64.53 | 2/147 | <0.0001 |
| Sleep disorders (z score) | -0.936 (0.141) ^{B,C} | 0.022 (0.105) ^A | 0.591 (0.121) ^A | 34.10 | 2/147 | <0.0001 |
| Fatigue (z score) | -1.036 (0.136) ^{B,C} | 0.167 (0.102) ^A | 0.519 (0.117) ^A | 40.42 | 2/147 | <0.0001 |
| Gastro-intestinal symptoms (z score) | -0.915 (0.143) ^{B,C} | 0.117 (0.107) ^{A,C} | 0.474 (0.123) ^{A,B} | 28.59 | 2/147 | <0.0001 |
| Cognitive disorders (z score) | -0.532 (0.163) ^{B,C} | 0.074 (0.122) ^A | 0.257 (0.140) ^A | 7.22 | 2/147 | 0.002 |

All results are shown as mean (SD) or as ratios. ^{A,B,C}posthoc comparisons among group means.

FF Fibro Fatigue scale, HAMD Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale; neuropsychiatric symptoms: z unit-based composite score based on FF, HAMD, and HAMA scores.

were not significant. P correction for FDR did not change any of these significant intergroup differences. Moreover, the ANTIOX index was significantly lower in both patient groups as compared with controls, and also in the total Long COVID group as compared with controls ($F = 17.46$, $df = 1/154$, $p < 0.001$).

Table 1 demonstrates the socio-demographic data in Long COVID patients divided into LC and LC + O&NS. No significant differences among these study groups were detected in BMI, residency, employment, education, vaccination status, and TUD. Age was somewhat higher in the LC + O&NS group, and there were more males in the LC + O&NS group than in the LC group. The disease duration was somewhat higher in LC + O&NS as compared with LC.

The same table also shows the medications patients were treated with during acute COVID-19 infection (enoxaparin, dexamethasone, ceftriaxone, azithromycin, bromhexin, levofloxacin) and Long COVID (antidepressants, namely sertraline ($n = 16$), fluoxetine ($n = 7$) and imipramine ($n = 6$), propranolol, chlorthalidopexide). We have examined the effects of these treatments on the rating scale scores and all biomarkers used in this study, but no significant effect of these treatments could be found (even without p correction for FDR), whilst the intergroup differences in rating scales and biomarkers remained significant (results of multivariate GLM).

Associations between LC clusters and symptoms of Long COVID

Table 2 shows the results of univariate GLM analysis examining the associations between diagnosis into controls, LC and LC + IO&NS and all clinical scores while controlling for the effects of age, sex, education years, and TUD (entered as covariates). We found that the total FF, HAMD and HAMA, somatic FF, HAMD and HAMA scores, depression HAMD and anxiety HAMA, as well as the autonomic and GIS symptoms, were significantly different between the three classes and increased from controls → LC → LC + O&NS. Sleep disorders, chronic fatigue and cognitive disorders were significantly higher in Long COVID than in controls.

Table 3 shows the intercorrelation matrix of the OSTOX/ANTIOX ratio and SpO2, PBT, and clinical ratings in the total study group and Long COVID patients separately. The OSTOX /ANTIOX ratio was significantly associated with all symptom scores. There were no significant associations between CRP and the OSTOX/ANTIOX ratio. Figure 1 shows the partial regression of the neuropsychiatric symptoms score on OSTOX/ANTIOX in the total sample after adjusting for age, sex, BMI, education and TUD. All significant correlations shown in this table remained significant after p correction for FDR.

Prediction of the symptom scores by IO&NS biomarkers

Table 4 shows the results of multiple regression analyses with somatic and affective measurements as dependent variables and O&NS biomarkers and CRP as explanatory variables while allowing for the effects of age, sex, BMI, TUD, education and vaccination types. Regression #1 shows that 25.0% of the variance in the depression HAMD score could be explained by the regression on Gpx and education (inversely associated) and MDA, CRP and carbonyl proteins (positively associated). We found that 23.0% of the variance in the somatic HAMD score (regression #2) was explained by the cumulative effects of lowered Gpx and zinc, increased NO and CRP and vaccination with AstraZeneca or Pfizer. Regression #3 shows that 13.1% of the variance in anxiety HAMA is explained by CRP, female sex and AstraZeneca vaccination. In Regression #4, 26.7% of the variance in somatic HAMA was explained by the regression on CRP and NO (positively) and Gpx (inversely), female sex and vaccination with AstraZeneca or Pfizer. Regression #5 shows that 28.0% of the variance in somatic FF was explained by NO, MDA, CRP (positively) and Gpx (inversely). Up to 30.2% of the variance in the severity of the neuropsychiatric symptom score was explained by NO, MDA, CRP (positively), Gpx (inversely), female sex, and vaccination with AstraZeneca or Pfizer.


Prediction of symptom scores by IO&NS biomarkers, SpO2 and body temperature

We have rerun the analyses shown in Table 4 and include the OSTOX, ANTIOX, OSTOX/ANTOX ratio, SpO2 and body

Table 3. Intercorrelations between immune, oxidative stress toxicity (OSTOX) and antioxidant (ANTIOX) indices and oxygen saturation (SpO₂), peak body temperature, C-reactive protein (CRP), and clinical rating scale scores.

| Variables | OSTOX /ANTIOX | | BTO2ONS index | |
|-------------------------------------|--------------------|--------------------|----------------|--------------------|
| | Total sample | Long COVID | Total sample | Long COVID |
| SpO ₂ | -0.405 | -0.328 | | |
| Body temperature | 0.277 | 0.032 [§] | | |
| CRP | 0.123 [§] | 0.079 [§] | 0.432 | 0.391 |
| Total HAMD | 0.388 | 0.356 | 0.710 | 0.516 |
| Total HAMA | 0.384 | 0.299 | 0.677 | 0.495 |
| Total FF | 0.417 | 0.358 | 0.705 | 0.502 |
| Depression HAMD | 0.371 | 0.307 | 0.604 | 0.342 |
| Somatic HAMD | 0.386 | 0.312 | 0.634 | 0.427 |
| Anxiety HAMA | 0.248 | 0.120 [§] | 0.472 | 0.270 |
| Somatic HAMA | 0.405 | 0.344 | 0.711 | 0.570 |
| Somatic FF | 0.417 | 0.358 | 0.732 | 0.535 |
| Neuropsychiatric symptoms (z score) | 0.435 | 0.376 | 0.752 | 0.574 |
| Autonomic symptoms (z score) | 0.388 | 0.310 | 0.713 | 0.515 |
| Sleep disorders (z score) | 0.298 | 0.232 [*] | 0.573 | 0.391 |
| Fatigue (z score) | 0.382 | 0.306 | 0.622 | 0.392 |
| GIS (z score) | 0.238 | 0.168 [§] | 0.514 | 0.306 |
| Cognitive disorders (z score) | 0.234 | 0.189 [*] | 0.338 | 0.202 [§] |
| <i>n</i> | <i>n</i> = 156 | <i>N</i> = 120 | <i>n</i> = 156 | <i>n</i> = 120 |

All at $p < 0.01$, except ^{*} $p < 0.05$ and [§]nonsignificant. The latter was computed in the total ($n = 156$) and the restricted sample ($n = 120$) of Long COVID patients. FF Fibro Fatigue scale, HAMD Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale, GIS gastrointestinal system, BTO2ONS a z unit-based composite score based on body temperature, SpO₂, OSTOX and ANTIOX.

**Fig. 1** Correlation between Long COVID symptoms and oxidative stress. Partial regression of the neuropsychiatric symptoms score on the oxidative stress toxicity/antioxidant (OSTOX/ANTIOX) ratio in patients with Long COVID and normal controls combined.

temperature and the results are presented in Table 5. SpO₂ was inversely associated with all 6 somatic and affective scores (regressions #1–#6), body temperature was positively associated with all scores, except anxiety HAMA, while IO&NS biomarkers had significant effects on all scores above and beyond the effects of SpO₂ and body temperature (all except anxiety HAMA). OSTOX was associated with depression HAMD, NO with somatic HAMD HAMA and FF, MDA predicted somatic FF and OSTOX/ANTIOX predicted the neuropsychiatric symptoms. The effects of CRP disappeared after considering the effects of the other explanatory variables.

In this Table, we also examine whether the OSTOX/ANTOX ratio and CRP are predicted by SpO₂ and body temperature while allowing for the effects of confounders. Regressions #7 and 8 display that the OSTOX/ANTIOX ratio was predicted by SpO₂ and CRP by body temperature and male sex. Figure 2 shows the partial

regression of the OSTOX/ANTIOX ratio on SpO₂ in the patient group in Long COVID and control participants combined. Figure 3 shows the partial regression of serum CRP on PBT during the acute phase of COVID-19 (performed in Long COVID and control participants combined). In addition, we have calculated the regressions of the same clinical rating scales on the biomarkers for participants with Long COVID only. Table 1 of the Electronic Supplementary File (ESF, Table 1) provides a summary of the results. The regression on SpO₂, OSTOX (NO), and ANTIOX (zinc, Gpx) markers, vaccination with AstraZeneca and Pfizer, and female sex explained a significant proportion of the variation in these clinical rating scales in subjects with Long COVID.

Associations between somatic and affective scores and all biomarkers combined

To examine the association between the combined effects of SpO₂, body temperature and the biomarkers of Long COVID, we performed two types of analyses: (a) Pearson's correlation analyses between the somatic and affective scores and a new composite score computed as z body temperature - SpO₂ + z OSTOX - z ANTIOX (dubbed the BTO2ONS index); and (b) canonical correlation analyses with the clinical scores as dependent variables and SpO₂, body temperature and a Long COVID biomarker composite score (z OSTOX + z CRP - z ANTIOX, dubbed the ONSCRIP index) as explanatory variables.

Table 3 shows that the BTO2ONS index was significantly correlated with CRP and with all clinical scores in the total study group and the restricted study group of Long COVID patients (except for cognitive disorders). Figure 4 shows the partial regression of the neuropsychiatric symptom score on the BTO2ONS composite score after controlling for age, sex, education and TUD in Long COVID patients. ESF Fig. 1 and Fig. 2 show the regressions of the somatic HAMA and FF scores, respectively, on the BTO2ONS index in Long COVID patients.

Table 4. Results of multiple regression analyses with somatic and affective symptom measurements as dependent variables and immune and oxidative and nitrosative stress biomarkers as explanatory variables.

| Regression | Explanatory variables | β | t | p | F model | df | p | R^2 |
|-------------------------------------|-----------------------|---------|-------|--------|--------------|--------------|------------------|--------------|
| #1. Depression HAMD | <i>Model</i> | | | | 10.01 | 5/150 | <0.001 | 0.250 |
| | Gpx | -0.203 | -2.82 | 0.006 | | | | |
| | MDA | 0.246 | 3.44 | <0.001 | | | | |
| | CRP | 0.248 | 3.47 | <0.001 | | | | |
| | Education | -0.211 | -2.94 | 0.004 | | | | |
| | Carbonyl proteins | 0.175 | 2.44 | 0.016 | | | | |
| #2. Somatic HAMD | <i>Model</i> | | | | 8.96 | 5/150 | <0.001 | 0.230 |
| | Gpx | -0.209 | -2.88 | 0.005 | | | | |
| | NO | 0.216 | 3.00 | 0.003 | | | | |
| | CRP | 0.223 | 3.11 | 0.002 | | | | |
| | Astra + Pfizer | 0.185 | 2.56 | 0.011 | | | | |
| | Zinc | -0.146 | -2.00 | 0.047 | | | | |
| #3. Anxiety HAMA | <i>Model</i> | | | | 6.76 | 3/152 | <0.001 | 0.131 |
| | Astra | 0.254 | 3.31 | 0.001 | | | | |
| | Female sex | 0.243 | -3.13 | 0.002 | | | | |
| | CRP | 0.218 | 2.76 | 0.006 | | | | |
| #4. Somatic HAMA | <i>Model</i> | | | | 10.95 | 5/150 | <0.001 | 0.267 |
| | CRP | 0.328 | 4.56 | <0.001 | | | | |
| | Gpx | -0.235 | -3.34 | 0.001 | | | | |
| | NO | 0.220 | 3.15 | 0.002 | | | | |
| | Astra or Pfizer | 0.193 | 2.76 | 0.006 | | | | |
| | Femal sex | 0.150 | 2.08 | 0.039 | | | | |
| | | | | | | | | |
| #5. Somatic FF | <i>Model</i> | | | | 14.65 | 4/151 | <0.001 | 0.280 |
| | Gpx | -0.268 | -3.86 | <0.001 | | | | |
| | CRP | 0.288 | 4.17 | <0.001 | | | | |
| | NO | 0.229 | 3.30 | 0.001 | | | | |
| | MDA | 0.199 | 2.86 | 0.005 | | | | |
| #6. Neuropsychiatric symptoms score | <i>Model</i> | | | | 10.73 | 6/149 | <0.001 | 0.302 |
| | Gpx | -0.254 | -3.67 | <0.001 | | | | |
| | CRP | 0.325 | 4.61 | <0.001 | | | | |
| | NO | 0.230 | 3.34 | 0.001 | | | | |
| | Astra + Pfizer | 0.161 | 2.35 | 0.020 | | | | |
| | Female sex | 0.153 | 2.17 | 0.032 | | | | |
| | MDA | 0.144 | 2.08 | 0.039 | | | | |

These regression analyses are performed in patients and controls combined.

Gpx Glutathione peroxidase, MDA malondialdehyde, TAC total antioxidant capacity, NO nitric oxide, MPO myeloperoxidase, OSTOX index of oxidative stress, ANTIOX index of antioxidant defenses, SpO2 peripheral oxygen saturation, FF Fibro-Fatigue scale, HAMD Hamilton Depression Rating scale, HAMA Hamilton Anxiety Rating scale, Astra + Pfizer vaccination with either AstraZeneca or Pfizer-BioNTech (versus Sinopharm S).

Table 6 shows the results of three canonical correlations with different sets of neuropsychiatric symptom scores as dependent variables. All CCAs showed that one canonical function was significant, while the other variates had no significant information about the variables. CCA #1 shows that the first canonical correlation between the biomarkers and total symptom scores was $r = 0.752$. The first canonical variate based on SpO2, body temperature and the ONSCRIP index explained 64.6% of the variance, indicating that this component is an overall measure of the adverse outcome pathways, and the first canonical variate based on the rating scale scores explained 89.4% of the variance indicating it is an overall measure of severity of the neuropsychiatric symptoms of Long COVID. Moreover, the amount of variance explained by the pathways in the total neuropsychiatric symptoms was 50.6%. The same biomarker set explained 41.6% of the variance

in a canonical variate extracted from somatic FF, HAMA and HAMD scores and anxiety HAMA and depression HAMD scores, and 39.1% in a canonical component based on autonomic and GIS symptoms, insomnia, and chronic fatigue, while the canonical loading of cognitive disorder was lower (0.421).

PLS and construction of a new endophenotypic class and a pathway phenotype

Figure 5 shows a PLS model that examined whether the effects of SpO2 and body temperature during the acute phase of the neuropsychiatric symptoms of Long COVID (a latent vector extracted from the 5 rating scale subdomains) are mediated by IO&NS biomarkers. Therefore, we entered all ONS biomarkers and CRP as single indicators that could be predicted by SpO2 or PBT, and whereby the ONS biomarkers, the overarching OSTOX/

Table 5. Results of multiple regression analyses with clinical measurements as dependent variables and oxidative stress toxicity (OSTOX) and antioxidant (ANTIOX) biomarkers as explanatory variables.

| Regression | Explanatory variables | β | t | p | F model | df | p | R^2 |
|-------------------------------------|-----------------------|---------|-------|--------|--------------|--------------|------------------|--------------|
| #1. Depression HAMD | Model | | | | 23.16 | 5/150 | <0.001 | 0.441 |
| | Body temperature | 0.390 | 5.12 | <0.001 | | | | |
| | OSTOX | 2.37 | 3.70 | <0.001 | | | | |
| | SpO2 | -0.195 | -2.49 | 0.014 | | | | |
| | Education | -0.161 | -2.59 | 0.011 | | | | |
| | Age | -0.137 | -2.21 | 0.028 | | | | |
| #2. Somatic HAMD | Model | | | | 30.59 | 4/151 | <0.001 | 0.448 |
| | SpO2 | -0.427 | -5.48 | <0.001 | | | | |
| | Body temperature | 0.238 | 3.14 | 0.002 | | | | |
| | Astra + Pfizer | 0.158 | 2.57 | 0.011 | | | | |
| | NO | 0.149 | 2.41 | 0.017 | | | | |
| #3. Depression HAMA | Model | | | | 26.14 | 3/152 | <0.001 | 0.340 |
| | SpO2 | -0.511 | -7.64 | <0.001 | | | | |
| | Female sex | 0.223 | -3.38 | <0.001 | | | | |
| | Astra + Pfizer | 0.133 | 1.99 | 0.048 | | | | |
| #4. Somatic HAMA | Model | | | | 41.14 | 5/150 | <0.001 | 0.578 |
| | SpO2 | -0.533 | -7.78 | <0.001 | | | | |
| | Body temperature | 0.241 | 3.61 | <0.001 | | | | |
| | Astra + Pfizer | -0.134 | 2.50 | 0.014 | | | | |
| | NO | 0.123 | 2.27 | 0.025 | | | | |
| | Femal sex | -0.114 | -2.13 | 0.035 | | | | |
| #5. Somatic FF | Model | | | | 53.60 | 4/151 | <0.001 | 0.587 |
| | SpO2 | -0.457 | -6.84 | <0.001 | | | | |
| | Body temperature | 0.322 | 4.95 | <0.001 | | | | |
| | NO | 0.151 | 2.80 | 0.006 | | | | |
| | MDA | 0.132 | 2.49 | 0.014 | | | | |
| #6. Neuropsychiatric symptoms score | Model | | | | 59.77 | 4/151 | <0.001 | 0.613 |
| | SpO2 | -0.531 | -8.02 | <0.001 | | | | |
| | Body temperature | 0.246 | 3.90 | <0.001 | | | | |
| | OSTOX/ANTIOX | 0.151 | 2.73 | 0.007 | | | | |
| | Female sex | 0.111 | 2.19 | 0.030 | | | | |
| #7. OSTOX/ANTIOX | Model | | | | 30.26 | 1/154 | <0.001 | 0.164 |
| | SpO2 | -0.405 | -5.50 | <0.001 | | | | |
| #9. CRP | Model | | | | 46.14 | 2/153 | <0.001 | 0.376 |
| | Body Temperature | 0.568 | 8.90 | <0.001 | | | | |
| | Male sex | 0.245 | 3.83 | <0.001 | | | | |

These regression analyses are performed in patients and controls combined.

Gpx Glutathione peroxidase, MDA malondialdehyde, NO nitric oxide, SpO2 peripheral oxygen saturation, FF Fibro-Fatigue scale, HAMD Hamilton Depression Rating scale, HAMA Hamilton Anxiety Rating scale, Astra + Pfizer vaccination with either AstraZeneca or Pfizer-BioNTech (versus Sinopharm S), CRP C-reactive protein.

ANTIOX ratio and CRP were allowed to predict the neuropsychiatric symptoms, which was entered as a latent vector extracted from somatic FF, HAMD and HAMA scores and depression HAMD and anxiety HAMA scores. With an SRMR of 0.027, the model quality was adequate, and we found adequate values for construct reliability validity of the neuropsychiatric symptoms (AVE = 0.731; composite reliability = 0.931, Cronbach alpha = 0.907, rho_A = 0.920, all loadings > 0.777). Blindfolding revealed appropriate construct cross-validated redundancy for the neuropsychiatric symptoms LV (0.424). Non-significant paths and non-significant indicators are deleted from the model. The following are the findings of the complete PLS analysis (bias-corrected and accelerated using 5000 bootstraps,) as shown in Fig. 5: a large

part of the variance in the neuropsychiatric symptoms (60.3%) is explained by female sex, body temperature, SpO2 and OSTOX/ANTIOX ratio. The effects of SpO2 on the neuropsychiatric symptoms score are in part mediated by effects on Gpx ($t = -2.21$, $p = 0.027$) and NO ($t = -2.05$, $p = 0.041$) which contribute to the OSTOX/ANTIOX ratio. Body temperature ($t = 4.02$, $p < 0.001$), SpO2 ($t = -9.14$, $p < 0.001$), zinc ($t = -2.74$, $p = 0.006$), TAC ($t = -2.90$, $p = 0.004$), Gpx ($t = -2.76$, $p = 0.006$), NO ($t = 2.75$, $p = 0.006$), MDA ($t = 2.85$, $p = 0.004$), and MPO ($t = 2.75$, $p = 0.006$), PCs ($t = 2.69$, $p = 0.007$) have significant total effects on the output latent vector.

Based on all variables entered in this model (except sex) and the latent neuropsychiatric symptoms score, we have performed a




Fig. 2 Correlation between oxidative stress and oxygen saturation in Long COVID. Partial regression of the oxidative stress toxicity/antioxidant (OSTOX/ANTIOX) ratio in Long COVID patients on peripheral blood oxygen saturation (SpO2) during the acute phase of COVID-19. This regression is performed in Long COVID and control participants.




Fig. 3 Correlation between CRP and body temperature during Long COVID. Partial regression of serum C-reactive protein (CRP) in Long COVID patients on peak body temperature during the acute phase of COVID-19. This regression is performed in Long COVID and control participants.

two-step cluster analysis with COVID infection as a categorical variable and all biomarkers as scale variables. Figure 6 shows the features of the formed clusters. We discovered a three-cluster model with an appropriate measure of cohesiveness and separation of 0.52, consisting of a control cluster ($n = 36$), patient cluster 1 ($n = 82$) and patient cluster 2 ($n = 38$). Figure 6 shows a clustered bar graph that was made using the significant indicators in the PLS analysis. Patient cluster 2 is a new endophenotype class of Long COVID characterized by very high body temperature, neuropsychiatric symptoms scores, MDA, MPO, PCs and NO values, and very low SpO2, Gpx, zinc and TAC values as compared with cluster 1 (all $p < 0.01$).

We also constructed a new pathway phenotype by extracting a factor from ONSCRP, SpO2, PBT, and the neuropsychiatric symptoms ($KMO = 0.782$, all loadings > 0.753 , explained variance = 68.5%, Cronbach alpha = 0.822).

DISCUSSION

Oxidative stress and immune activation in Long COVID

The current study's first major finding is that (a) Long COVID is associated with decreased ANTIOX, including Gpx, and a mild inflammatory process; and (b) 31.7% of Long COVID patients belong to a cluster characterized by decreased SpO2, antioxidant levels, zinc, and Gpx, and increased body temperature, CRP, and OSTOX (increased MPO, NOx, MDA, and (PCs)). To put it another way, Long COVID is associated with immune-inflammatory processes and decreased ANTIOX, while a subgroup of Long COVID patients additionally exhibits increased NO production,




Fig. 4 Correlation between Long COVID symptoms and immune-oxidative pathways. Partial regression of the neuropsychiatric symptoms score in Long COVID patients on a composite score based on increased oxidative stress toxicity and reduced antioxidant defences, peak body temperature and peripheral oxygen saturation (PBT + SpO2 + OSTOX). This regression is performed in Long COVID participants only.

oxidative damage to proteins (PCs) and lipids with increased aldehyde formation (MDA), and an immune-oxidative stress response (increased MPO and CRP).

Previous research found that between 1.8 and 24.5% of Long COVID patients had elevated CRP levels [11, 59–62], which were operationalized as > 10 mg/L or > 2.9 mg/dL. Other authors found that the median CRP levels varied between 0.6 and 2.9 mg/L [4, 63–65]. Nevertheless, in the present study, we detected that the patient group with Long COVID showed increased CRP levels compared with control levels, indicating a mild inflammatory response. Previously, a meta-analysis reported that 13 out of 14 studies showed increases in at least one measure of inflammation either in a subgroup of patients or throughout the whole post-COVID period [66]. In addition, more CD4 + T cells expressed interferon- γ and interleukin (IL)-2, and increased plasma levels of IL-6, macrophage inflammatory protein 1, IL-1 β , tumor necrosis factor-alpha and the soluble IL-1 receptor antagonist in the Long COVID patients [59, 62, 63, 67–70], indicating activation of M1 macrophages and T helper (Th)-1 phenotypes [33]. Mehandru and Merad reviewed that Long COVID is accompanied by elevated neutrophils, lipid abnormalities, and reduced serum albumin [71].

There are some data that acute COVID-19 infection is accompanied by signs of oxidative stress, including increased expression of ROS-response genes and glycolysis in peripheral blood mononuclear cells [72], increased MDA (TBARS assay), F-isoprostane, 8-hydroxy-2'-deoxyguanosine, AOPP and nitrotyrosine levels, and lowered glutathione (GSH), -SH groups, selenium, zinc, TAC and vitamin D [49, 73–79]. Lage et al. reported that activation of the NLRP3 inflammasome, including increased mitochondrial superoxide production and lipid peroxidation, may persist after short-term patient recovery [80].

As such, our work demonstrates that the oxidative stress biomarkers during Long COVID are quite similar to those found during the acute phase, except for AOPP, nitrotyrosine and TAC levels, which were altered in acute COVID-19 but not in Long COVID. Nonetheless, our study demonstrates that a persistent imbalance between oxidative stress toxicity and reduced ANTIOX is a key component of Long COVID and that increased aldehyde, neutrophil-associated MPO, protein carbonyl, and NO production are the major neurotoxic pathways, which, when combined with decreased ANTIOX, may have a variety of detrimental effects as reviewed before [81].

Given that the Long COVID group as a whole showed Gpx deficiency, while only a subset of patients demonstrated oxidative damage, we may infer that Gpx deficiency is the main cause of the consequent lipid and protein damage. Gpx has been shown to degrade lipid hydroperoxides to their respective alcohols and free

Table 6. Results of canonical correlation analysis (CCA) with symptom scores as dependent variables and biomarkers of acute and Long COVID-19 as explanatory variables.

| Sets | CCA #1. Total FF, HAMD, HAMA | | CCA #2. Subdomains of FF, HAMA, HAMD | | CCA #3. Somatic symptoms | |
|------------|------------------------------|---------------|--------------------------------------|--------------------|--------------------------|----------------|
| | Variables | C Loadings | Variables | C Loadings | Variables | C Loadings |
| Set PA | FF total | 0.953 | Depression HAMD | 0.736 | Autonomic ss | 0.959 |
| | HAMA total | 0.934 | Somatic HAMD | 0.808 | Sleep disorders | 0.788 |
| | HAMD total | 0.950 | Anxiety HAMA | 0.634 | Chronic fatigue | 0.817 |
| | | | Somatic HAMA | 0.927 | GIS symptoms | 0.717 |
| | | Somatic FF | 0.941 | Cognitive symptoms | – | |
| Set BM | SpO2 | –0.956 | SpO2 | –0.939 | SpO2 | –0.915 |
| | PBT | 0.793 | PBT | 0.817 | PBT | 0.854 |
| | ONSCRIP index | 0.629 | ONSCRIP index | 0.659 | ONSCRIP index | 0.668 |
| Statistics | F (df) | 17.32 (9/365) | | 12.88 (15/408) | | 14.42 (12/394) |
| | p | <0.001 | | <0.001 | | <0.001 |
| | Correlation | 0.752 | | 0.764 | | 0.758 |
| | Set PA/set BM | 0.506 | | 0.416 | | 0.391 |
| | Set PA by self | 0.894 | | 0.669 | | 0.681 |
| | Set BM by self | 0.646 | | 0.661 | | 0.671 |

These analyses are performed in patients and controls combined.

C Loadings Canonical Loadings, *Set PA* somatic and affective set, *Set BM* biomarker set.

OSTOX index of oxidative stress toxicity, *ANTIOX* index of antioxidants, *ONSCRIP* composite based on *OSTOX*, *ANTIOX* and *CRP* (C-reactive protein), *SpO2* peripheral oxygen saturation, *PBT* peak body temperature, *FF* Fibro Fatigue scale, *HAMD* Hamilton Depression Rating scale, *HAMA* Hamilton anxiety rating scale, *GIS* gastrointestinal symptoms.

hydrogen peroxide to water [82, 83], hence reducing oxidative damage [81]. Due to their negative impact on the vascular endothelium and inflammatory processes, these activated oxidative stress pathways contribute to the pathophysiology of COVID-19 and Long COVID [84–86]. In addition, MPO generated by neutrophils during inflammation may result in irreversible protein and lipid alterations and increased levels of oxidized low-density lipoprotein, thereby promoting atherogenesis [87]. Furthermore, the resulting chlorinative stress may lead to multiorgan damage in COVID-19 through various mechanisms, including oxygen competition for heme-binding sites, decreased oxygen saturation, hemoglobin-heme iron oxidation, heme degradation, and iron release [88]. Although NO production was enhanced considerably in Long COVID, nitrotyrosine levels were not altered, although increased nitrotyrosine indicates an increase in reactive nitrogen species with increased NO₂ binding to tyrosine, thereby forming an immunogenic neoepitope [89]. Nonetheless, future research should explore if the increased NO generation in Long COVID results in nitrosative stress associated with hypernitrosylation (increased NO or nitroso binding), which has a variety of neurotoxic consequences [90]. It is critical to remember that low zinc levels have a wide impact on the immune system [91, 92] and that zinc itself may reduce viral replication, including SARS-CoV-2 replication [93].

Biomarkers of acute COVID-19 predict IO&NS biomarkers of Long COVID

The second major finding of this study is that decreased SpO₂ levels during the acute phase of COVID-19 significantly predict OSTOX, increased NO production, and decreased Gpx and ANTIOX, whereas increased PBT levels during the acute phase predict increased CRP and decreased zinc and antioxidant levels in Long COVID. As a result, both decreased SpO₂ and higher body temperature contribute to Long COVID's increased OSTOX/ANTIOX ratio.

As mentioned in the Introduction, both lowered SpO₂ and increased body temperature are part of the immune-inflammatory

response, predict critical illness and death, and are manifestations of the infectious-immune-inflammatory core of acute COVID-19 [94]. SpO₂ is often lowered in COVID-19, particularly in more severe instances and in the presence of CCTAs [95, 96], and both CCTAs and decreased SpO₂ are highly related to immunological activation [25]. COVID-19-associated microvascular damage, such as endothelitis, microthrombosis, capillary damage, damage to pericytes, and fluid buildup in the alveoli, results in hypoxia and reduced SpO₂ [97]. Prolonged systemic hypoxia has been shown to affect the redox equilibrium and induce oxidative stress [98, 99]. These effects drive inflammatory processes and nitro-oxidative pathways [100] and the resultant excess of reactive oxygen species may induce oxidative damage, aggravating systemic tissue damage and contributing to more severe COVID-19 [101]. COVID-19 individuals who require invasive mechanical breathing, admission to an intensive care unit, or lengthy hospitalization are more likely to sustain long-term tissue damage as a result of persistent symptoms [102–104]. As such, it appears that COVID-19 (and other viral infectious diseases) is accompanied by three different inflammatory phases: (a) beneficial protective inflammation, which combats the infection and may mount a restorative repair, (b) hyperinflammation, which may lead to a cytokine storm and critical disease or even death, and (c) non-resolving inflammation resulting in a protracted mild inflammatory state [105] as observed in Long COVID. All in all, our results show that the severity of the infectious-immune-inflammatory response during acute COVID-19 may, at least in part, predict mild inflammation and increased nitro-oxidative damage in Long COVID.

IO&NS biomarkers predict the neuropsychiatric symptoms of Long COVID

The third and most noteworthy finding of this study is the discovery of (a) a pathway phenotype comprising SpO₂, body temperature, OSTOX, ANTIOX, CRP and increased neuropsychiatric symptoms; and (b) an endophenotype class of Long COVID patients (31.7%) who show simultaneously severe abnormalities in




Fig. 5 Results of Partial Least Squares (PLS) analysis. This model shows that the effects of reduced oxygen saturation (SpO2) and increased peak body temperature (PBT) during the acute phase of COVID-19 on the neuropsychiatric symptoms (NPS) of Long COVID are in part mediated by increased oxidative stress toxicity and lowered antioxidant defenses. The neuropsychiatric symptoms of Long COVID are entered as a latent vector extracted from subdomain scores on the Fibromyalgia-Fatigue (FF), Hamilton Depression (HAMD) and Anxiety (HAMA) rating scales. sFF somatic FF symptoms, sHAMD and sHAMA somatic HAMD and HAMA scores, respectively, dHAMD depression HAMD scores, aHAMA anxiety HAMA scores, CRP C-reactive protein, Gpx glutathione peroxidase, TAC total antioxidant capacity, MPO myeloperoxidase, MDA malondialdehyde. Shown are path coefficients (with exact *p* values between brackets), loadings (with *p* values) of the latent vector and explained variance (white figures in blue circles).




Fig. 6 Results of clustering analysis. Results of cluster analysis with the formation of a new endophenotype class of patients with Long COVID (cluster 2) which is characterized by increased PBT (peak body temperature) and lowered peripheral oxygen saturation (SpO2) during acute COVID-19, and lowered zinc, Gpx (glutathione peroxidase) and TAC (total antioxidant capacity), and increased MDA (malondialdehyde), MPO (myeloperoxidase), NO (nitric oxide), PC (protein carbonyls), OSTOX/ANTIOX (oxidative stress toxicity/antioxidant defenses) ratio, CRP (C-reactive protein) and severity of the neuropsychiatric symptoms (NPS) 3–4 months after the acute phase (Long COVID).

SpO2 and PBT during acute COVID-19, and an increased OSTOX/ANTIOX ratio, CRP and increased total HAMD, HAMA and FF total and subdomain scores during Long COVID. The HAMD score, for example, was 4.9 points higher in this endophenotype class as

compared with the other patient group. The changes in the rating scale scores indicate the presence of moderate depression and anxiety symptoms consistent with major depression and GAD and the presence of a chronic fatigue syndrome (lasting 2–3 months), including chronic fatigue, insomnia, autonomic and gastrointestinal symptoms, and, to a lesser extent, cognitive impairments. In addition, ~60% of the variance in the severity of the neuropsychiatric symptoms is explained by the cumulative effects of decreased SpO2 and increased PBT (thus, the severity of the acute infectious phase) coupled with increased CRP and OSTOX/ANTIOX ratio. Most notably was the impact of MDA and NO and decreased Gpx and zinc, although PCs and MPO, as well as decreased TAC, all contribute to neuropsychiatric symptoms.

According to a recent meta-analysis, the percentage of people suffering chronic fatigue 12 weeks or more after exposure to COVID-19 was 0.32, whereas cognitive impairment was 0.22 [66]. In addition, a narrative synthesis indicated that a subgroup of Long COVID patients had elevated proinflammatory indicators and significant functional impairment. Another meta-analysis found that 80% of patients infected with SARS-CoV-2 had one or more long-term symptoms and that the top most typical symptoms were chronic fatigue (58%), headache (44%), attention problems (27%), hair loss (25%), and dyspnea (24%), although memory loss, anxiety, depression, insomnia, digestive disorders, and autonomic symptoms were also widespread (from 10 to 20%) 15–110 days after virus infection [106]. Mehandru and Merad reviewed the many clinical manifestations of long-haul COVID, including systemic and musculoskeletal manifestations (chronic fatigue

and fibromyalgia symptoms), psychiatric symptoms (insomnia, depression, anxiety, neurocognitive deficits), autonomic and cardiovascular, GIS and renal and respiratory manifestations [71]. According to some other studies, 50–98% of the Long COVID patients complain of fatigue as the primary symptom [1, 12, 107]. In addition, mood abnormalities are common [2], particularly despair and anxiety [23], whereas 58.4% of Long COVID patients have cognitive impairment and 34–51–78% have memory problems, particularly memory loss [2, 18, 22, 104, 108]. In addition, other studies indicate that dyspnea, autonomic symptoms, post-traumatic stress and fibromyalgia symptoms (muscle aches, myalgia, and articular pain) are common [109–111]. Notably, the severity of acute COVID-19 infection affects the development of neuropsychiatric symptoms, with ICU survivors being more likely (56%) than non-ICU survivors to develop a neuropsychiatric condition [24]. Most importantly, the results of our study show that chronic fatigue, depression and anxiety symptoms in Long COVID are all manifestations of the same core, which is strongly associated with OSTOX/ANTIOX and inflammatory signs

There is now evidence that major depression, GAD and chronic fatigue syndrome are IO&NS-related disorders characterized by increased levels of inflammatory mediators, including CRP, oxidative damage to lipids with increased aldehyde formation, damage to proteins, increased NO production and hypernitrosylation and lowered antioxidant levels including zinc, GSH and Gpx and TAC [28, 31, 81, 112]. We have reviewed previously the mechanistic explanations of how these multiple IO&NS pathways cause neuroaffective toxicity and, consequently, the onset of chronic fatigue syndrome and somatic and affective symptoms [28, 31, 81, 112–114]. All in all, the hyperinflammation that may accompany SARS-CoV-2 infection is not only associated with severe lung pathology [115, 116], a poorer clinical outcome [115, 117] and higher mortality [118] but also with increased OSTOX/ANTIOX and somatic and mental symptoms some months later. It should be stressed that only part of the variance in Long COVID somatic and mental symptoms was explained by IO&NS pathways indicating that other mechanistic processes are involved. In this respect, it is plausible that autoimmune responses, which play a role in chronic fatigue syndrome and depression [28, 119] and Long COVID [120], and pulmonary fibrosis with scarring and cardiac remodeling [71] contribute to neuropsychiatric symptoms.

Finally, it is also important to note that vaccinations with AstraZeneca (viral vector, genetically modified virus vaccine) and Pfizer (mRNA vaccine), but not Sinopharm (inactivated virus vaccine), may aggravate the neuropsychiatric symptoms and, in particular, the somatic symptoms of HAMA and HAMD. It is known that this type of corona vaccines may cause Long COVID-like symptoms, including anxiety, depression and fatigue, T cell activation, autoimmune responses, increased production of spike protein, and impairments in type 1 interferon signaling [121, 122].

Limitations

Follow-up studies should examine the same rating scales and biomarkers at later time points, including 6 months, 1 and 2 years after the acute infection, to delineate which patients show protracted chronic fatigue syndrome and GAD (which tend to be chronic disorders) and remitted depression (which most often comes in short-lasting episodes) [54, 105]. The data are correlative, and therefore no cause-and-effect determinations can be made. It is interesting to note that some of the Long COVID individuals, namely those with less severe symptoms and lowered ANTIOX without changes in OSTOX, showed increased inflammation during acute COVID-19. Thus, future studies should include other inflammation-related biomarkers which may explain part of the variance in the clinical neuropsychiatric symptoms, including

autoimmune responses, the cytokine network, the NLRP3 inflammatory, and hypernitrosylation.

CONCLUSIONS

Around 60% of the variation in the neuropsychiatric symptoms of Long COVID is explained by OSTOX/ANTIOX, PBT and SpO₂. Lowered SpO₂ predicts the alterations in Gpx and NO production during Long COVID, while increased body temperature predicts increased CRP and reduced ANTIOX and zinc levels in Long COVID. The impact of the immune-inflammatory response during acute COVID-19 on the neuropsychiatric symptoms of Long COVID is partially mediated by OSTOX/ANTIOX. Post-viral somatic and mental affective symptoms have an inflammatory origin and are partially mediated by neuro-oxidative damage and lowered ANTIOX.

DATA AVAILABILITY

The dataset generated during and/or analyzed during the current study will be available from the corresponding author (MM) upon reasonable request and once the dataset has been fully exploited by the authors.

REFERENCES

- Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open*. 2021;11:e048391.
- Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al. Cerebral Micro-Structural Changes in COVID-19 Patients - An MRI-based 3-month Follow-up Study. *EclinicalMedicine*. 2020;25:100484.
- Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. *Open Forum Infect Dis*. 2020;7:ofaa507.
- van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*. 2021;73:e1089–98.
- Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, et al. Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. *Ann Am Thorac Soc*. 2021;18:997–1003.
- Mahase E. Covid-19: What do we know about "long covid"? *BMJ*. 2020;370:m2815.
- Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. *Int J Environ Res Public Health*. 2021;18:2621.
- Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. *Diabetes Metab Syndr*. 2021;15:869–75.
- Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ*. 2021;372:n136.
- Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis*. 2021;53:737–54.
- Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax*. 2021;76:399–401.
- Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;324:603–5.
- Rubin GJ, Smith LE, Melendez-Torres GJ, Yardley L. Improving adherence to 'test, trace and isolate'. *J R Soc Med*. 2020;113:335–8.
- Miller A. COVID-19: not just an acute illness. *Trends Urol Men Health*. 2020;11:17–9.
- Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. *Clin Med (Lond)*. 2021;21:e63–7.
- Macpherson K, Cooper K, Harbour J, Mahal D, Miller C, Nairn M. Experiences of living with long COVID and of accessing healthcare services: a qualitative systematic review. *BMJ Open*. 2022;12:e050979.
- Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, Vera-Urbe R, Torralba Y, Alsina-Restoy X, et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *Chron Respir Dis*. 2021;18:14799731211002240.

18. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
19. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *J Neuroviro*. 2021;27:154–9.
20. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppego P, Avanzi GC, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. *JAMA Netw open*. 2021;4:e2036142–e2036142.
21. Cirulli ET, Schiabor Barrett KM, Riffle S, Bolze A, Neveux I, Dabe S et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv* 2020: 2020.2010.2007.20208702.
22. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect*. 2020;81:e4–6.
23. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397:220–32.
24. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiat*. 2021;8:416–27.
25. Al-Jassas HK, Al-Hakeim HK, Maes M. Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach. *J Affect Disord*. 2022;297:233–45.
26. Al-Hadrawi DS, Al-Rubaye HT, Almulla AF, Al-Hakeim HK, Maes MF. Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to LONG COVID: a precision nomothetic approach. *Acta Neuropsychiatrica*. 2022:1–12.
27. Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. *Crit Care*. 2020;24:298.
28. Maes M. Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self. *J Pers Med*. 2022;12:403.
29. Sagulkoo P, Plaimas K, Suratane A, Colado Simão AN, Vissoci Reiche EM, Maes M. Immunopathogenesis and immunogenetic variants in COVID-19. *Curr Pharm Des*. 2022 May. <https://doi.org/10.2174/1381612828666220519150821>. Epub ahead of print. PMID: 35598232.
30. Maes M. An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:784–94. 10.1016/j.pnpbp.2010.06.023. Epub 2010 Jul 4. PMID: 20609377
31. Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Galecki P, et al. The immune profile of Major Dystonia Disorder: Proof of concept and mechanism using the precision nomothetic psychiatry approach. *Cells*. 2022;11:1183.
32. Liu T, Zhong S, Liao X, Chen J, He T, Lai S, et al. A Meta-Analysis of Oxidative Stress Markers in Depression. *PLoS ONE*. 2015;10:e0138904.
33. Maes M, Carvalho AF. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. *Mol Neurobiol*. 2018;55:8885–903.
34. Maes M, Moraes JB, Bonifacio KL, Barbosa DS, Vargas HO, Michelin AP, et al. Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach. *Metab Brain Dis*. 2021;36:509–21.
35. Luduvico KP, Spohr L, Soares MSP, Teixeira FC, de Farias AS, Bona NP, et al. Antidepressant Effect and Modulation of the Redox System Mediated by Tannic Acid on Lipopolysaccharide-Induced Depressive and Inflammatory Changes in Mice. *Neurochem Res*. 2020;45:2032–43.
36. Pereira GC, Piton E, Dos Santos BM, da Silva RM, de Almeida AS, Dalenogare DP, et al. Apocynin as an antidepressant agent: in vivo behavior and oxidative parameters modulation. *Behav Brain Res*. 2020;388:112643.
37. Anggreini P, Ardianto C, Rahmadi M, Khotib J. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation. *J Basic Clin Physiol Pharmacol*. 2019;30.
38. Lee JS, Kim HG, Han JM, Kim YA, Son CG. Anti-fatigue effect of Myelophil in a chronic forced exercise mouse model. *Eur J Pharm*. 2015;764:100–8.
39. Hong SS, Lee JY, Lee JS, Lee HW, Kim HG, Lee SK, et al. The traditional drug Gongjin-Dan ameliorates chronic fatigue in a forced-stress mouse exercise model. *J Ethnopharmacol*. 2015;168:268–78.
40. Nicosia N, Kwiecień I, Mazurek J, Mika K, Bednarski M, Miceli N, et al. Hydroalcoholic Leaf Extract of *Isatis tinctoria* L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. *Oxid Med Cell Longev*. 2022;2022:3567879.
41. Kanchanatawan B, Tangwongchai S, Sughondhabhirom A, Suppavitorn S, Hemrunroj S, Carvalho AF, et al. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. *Neurotox Res*. 2018;33:621–33.
42. Ali S, Corbi G, Maes M, Scapagnini G, Davinelli S. Exploring the Impact of Flavonoids on Symptoms of Depression: A Systematic Review and Meta-Analysis. *Antioxid (Basel)*. 2021;10:1644.
43. Gautam M, Agrawal M, Gautam M, Sharma P, Gautam AS, Gautam S. Role of antioxidants in generalised anxiety disorder and depression. *Indian J Psychiatry*. 2012;54:244–7.
44. Castro-Marrero J, Domingo JC, Cordobilla B, Ferrer R, Giralte M, Sanmartín-Sentañes R, et al. Does Coenzyme Q10 Plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? *Antioxid Redox Signal*. 2022;36:729–39.
45. Pincemail J, Cavalier E, Charlier C, Cheramy-Bien J-P, Brevers E, Courtois A, et al. Oxidative Stress Status in COVID-19 Patients Hospitalized in Intensive Care Unit for Severe Pneumonia. A Pilot Study. *Antioxidants*. 2021;10:257.
46. Mehri F, Rahbar AH, Ghane ET, Souiri B, Esfahani M. Changes in oxidative markers in COVID-19 patients. *Arch Med Res*. 2021;52:843–9.
47. Solis-Paredes J, Montoya-Estrada A, Cruz-Rico A, Reyes-Muñoz E, Perez-Duran J, Espino y Sosa S, et al. Plasma Total Antioxidant Capacity and Carbonylated Proteins Are Increased in Pregnant Women with Severe COVID-19. *Viruses*. 2022;14:1–10.
48. Ducastel M, Chenevier-Gobeaux C, Ballaa Y, Meritet JF, Brack M, Chapuis N, et al. Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19. *Int J Mol Sci*. 2021;22:7462.
49. Soto ME, Guarner-Lans V, Díaz-Díaz E, Manzano-Pech L, Palacios-Chavarría A, Valdez-Vázquez RR, et al. Hyperglycemia and Loss of Redox Homeostasis in COVID-19 Patients. *Cells*. 2022;11:932.
50. Taylor EW, Radding W. Understanding Selenium and Glutathione as Antiviral Factors in COVID-19: Does the Viral M(pro) Protease Target Host Selenoproteins and Glutathione Synthesis? *Front Nutr*. 2020;7:143.
51. Ghanei E, Baghani M, Moravvej H, Talebi A, Abdollahimajd F. Low serum levels of zinc and 25-hydroxyvitamin D as potential risk factors for COVID-19 susceptibility: a pilot case-control study. *Eur J Clin Nutr*. 2022;76:1297–302.
52. WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021: World Health Organization; 2021; https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
53. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960;23:56–62.
54. Morris G, Maes M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. *Metab Brain Dis*. 2013;28:523–40.
55. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). *J Psychosom Res*. 2002;52:501–9.
56. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol*. 1959;32:50–5.
57. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B Stat Methodol*. 1995;57:289–300.
58. Ringle C, Da Silva D, Bido D. Structural equation modeling with the SmartPLS. *Braz J Market*. 2015;13.
59. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. *Eur Respir J*. 2021;57:2003481.
60. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *Lancet Respir Med*. 2021;9:1275–87.
61. Skala M, Svoboda M, Kopecky M, Kocova E, Hyrsil M, Homolac M, et al. Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia. *Virology*. 2021;18:1–5.
62. Santis L, Pérez-Camacho I, Sobrino B, González GE, Ruiz-Mesa JD, Plata A et al. Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study. *Epidemiol Int J*. 2021;4:1–7.
63. Zhou Y, Teng X, Han M, Shi J, Li C, Zhang X, et al. The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19. *Eur Rev Med Pharm Sci*. 2021;25:1097–100.
64. García-Abellán J, Padilla S, Fernández-González M, García JA, Agulló V, Andreo M et al. Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: antibody response predicts long COVID. *medRxiv* 2021.
65. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? *Lung*. 2021;199:113–9.

66. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Beh Immun*. 2022;101:93–135.
67. Breton G, Mendoza P, Hägglöf T, Oliveira TY, Schaefer-Babajew D, Gaebler C et al. Persistent cellular immunity to SARS-CoV-2 infection. *J Exp Med*. 2021;218:e20202515.
68. Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open Forum Infect Dis*. 2021;8:ofab156.
69. Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. Alterations in T and B cell function persist in convalescent COVID-19 patients. *Med*. 2021;2:720–35.e724.
70. Fortini A, Torrigiani A, Sbaragli S, Lo Forte A, Crociani A, Cecchini P, et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. *Infection*. 2021;49:1007–15.
71. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol*. 2022;23:194–202.
72. Medini H, Zirman A, Mishmar D. Immune system cells from COVID-19 patients display compromised mitochondrial-nuclear expression co-regulation and rewiring toward glycolysis. *Iscience*. 2021;24:103471.
73. Kumar DS, Hanumanram G, Suthakaran PK, Mohanan J, Nair LDV, Rajendran K. Extracellular Oxidative Stress Markers in COVID-19 Patients with Diabetes as Comorbidity. *Clin Pr*. 2022;12:168–76.
74. Kosanovic T, Sagic D, Djukic V, Pljesa-Ercegovac M, Savic-Radojevic A, Bukumiric Z et al. Time Course of Redox Biomarkers in COVID-19 Pneumonia: Relation with Inflammatory, Multiorgan Impairment Biomarkers and CT Findings. *Antioxidants (Basel)*. 2021;10:1126.
75. Skesters A, Kustovs D, Lece A, Moreino E, Petrosina E, Rainsford KD. Selenium, selenoprotein P, and oxidative stress levels in SARS-CoV-2 patients during illness and recovery. *Inflammopharmacology*. 2022;30:499–503.
76. Yaghoubi N, Youssefi M, Jabbari Azad F, Farzad F, Yavari Z, Zahedi Avval F. Total antioxidant capacity as a marker of severity of COVID-19 infection: Possible prognostic and therapeutic clinical application. *J Med Virol*. 2022;94:1558–65.
77. Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, Sekar P, et al. COVID-19: Poor outcomes in patients with zinc deficiency. *Int J Infect Dis*. 2020;100:343–9.
78. Yasui Y, Yasui H, Suzuki K, Saitou T, Yamamoto Y, Ishizaka T, et al. Analysis of the predictive factors for a critical illness of COVID-19 during treatment — relationship between serum zinc level and critical illness of COVID-19. *Int J Infect Dis*. 2020;100:230–6.
79. Lambadiari V, Mitrakou A, Kountouri A, Thymis J, Katogiannis K, Korakas E, et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. *Eur J Heart Fail*. 2021;23:1916–26.
80. Lage SL, Amaral EP, Hilligan KL, Laidlaw E, Rupert A, Namasivayan S, et al. Persistent Oxidative Stress and Inflammation Activation in CD14(high)CD16(-) Monocytes From COVID-19 Patients. *Front Immunol*. 2021;12:799558.
81. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:676–92.
82. El-Far MA, Bakr MA, Farahat SE, Abd El-Fattah EA. Glutathione peroxidase activity in patients with renal disorders. *Clin Exp Nephrol*. 2005;9:127–31.
83. Herbette S, Roedel-Drevet P, Drevet JR. Seleno-independent glutathione peroxidases. *FEBS J*. 2007;274:2163–80.
84. Chernyak B, Popova E, Prikhodko A, Grebenchikov O, Zinovkina L, Zinovkin R. COVID-19 and oxidative stress. *Biochem (Mosc)*. 2020;85:1543–53.
85. Fodor A, Tiperciuc B, Login C, Orasan OH, Lazar AL, Buchman C et al. Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets. *Oxid Med Cell Long*. 2021;2021:8671713.
86. Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. *Front Cell Infect Microbiol*. 2021;11:654813.
87. Karahocagil MK, Aslan M, Ceylan MR, Cikman A, Sunnetcioglu M, Kucukoglu ME, et al. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. *Clin Biochem*. 2012;45:733–6.
88. McGonagle D, Sharif K, O'Regan A, Bridgwood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmun Rev*. 2020;19:102537.
89. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, et al. Oxidative & nitrosative stress in depression: why so much stress? *Neurosci Biobehav Rev*. 2014;45:46–62.
90. Morris G, Maes M. Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). *Curr Neuropharmacol*. 2014;12:168–85.
91. Prasad AS. Discovery of human zinc deficiency: its impact on human health and disease. *Adv Nutr*. 2013;4:176–90.
92. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. *Nutrients*. 2017;9:624.
93. Kumar A, Kubota Y, Chernov M, Kasuya H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. *Med Hypotheses*. 2020;144:109848.
94. Al-Hakeim HK, Al-Jassas HK, Morris G, Maes M. Increased ACE2, sRAGE, and immune activation, but lowered calcium and magnesium in COVID-19. *Recent Adv Inflamm Allergy Drug Discov*. 2022;16:32–43.
95. Dai W-C, Zhang H-W, Yu J, Xu H-J, Chen H, Luo S-P, et al. CT imaging and differential diagnosis of COVID-19. *Can Assoc Radio J*. 2020;71:195–200.
96. Luks AM, Swenson ER. COVID-19 Lung Injury and High-Altitude Pulmonary Edema: A False Equation with Dangerous Implications. *Ann Am Thorac Soc*. 2020;17:918–21.
97. Sarkar M, Niranjan N, Banyal PK. Mechanisms of hypoxemia. *Lung India*. 2017;34:47–60.
98. Debevec T, Millet GP, Pialoux V. Hypoxia-Induced Oxidative Stress Modulation with Physical Activity. *Front Physiol*. 2017;8:84.
99. Pialoux V, Mounier R. Hypoxia-induced oxidative stress in health disorders. *Oxid Med Cell Longev*. 2012;2012:940121.
100. McGarry T, Biniacka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. *Free Radic Biol Med*. 2018;125:15–24.
101. Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETWORK in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. *Adv Biol Reg*. 2020;77:100741.
102. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine*. 2021;31:100683.
103. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol*. 2021;93:1013–22.
104. Taboada M, Cariñena A, Moreno E, Rodríguez N, Domínguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. *J Infect*. 2021;82:e31–3.
105. Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. *BMC Med*. 2012;10:66.
106. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2021;11:1–12.
107. Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. *J Korean Med Sci*. 2020;35:e418.
108. Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. *Brain Commun*. 2020;2:fcaa205.
109. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ*. 2021;374:n1648.
110. Stefano GB. Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID. *Med Sci Monit*. 2021;27:e931447.
111. Dotan A, David P, Arnheim D, Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. *Autoimmun Rev*. 2022;21:103071.
112. Maes M, Bonifacio KL, Morelli NR, Vargas HO, Moreira EG, St Stoyanov D, et al. Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses. *Neurotox Res*. 2018;34:489–510.
113. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci Biobehav Rev*. 2012;36:764–85.
114. Morris G, Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). *Curr Neuropharmacol*. 2014;12:168–85.
115. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506.
116. Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. *Infect Dis Clin North Am*. 2019;33:869–89.
117. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*. 2020;71:762–8.

118. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180:934–43.
119. Simeonova D, Stoyanov D, Leunis J-C, Murdjeva M, Maes M. Construction of a nitro-oxidative stress-driven, mechanistic model of mood disorders: a nomothetic network approach. *Nitric Oxide.* 2021;106:45–54.
120. Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: implications for Autoimmune Diseases. *Front Immunol.* 2020;11:617089.
121. Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs. *Authorea Preprints.* 2022;164.
122. Couzin-Frankel J, Vogel G. Vaccines may cause rare, Long Covid-like symptoms. *Sci (N. Y., NY).* 2022;375:364–6.

ACKNOWLEDGEMENTS

We thank the staff of Al-Sadr Teaching Hospital and Al-Amal Specialized Hospital for Communicable Diseases in Najaf governorate-Iraq for their help in collecting samples. We also thank the high-skilled staff of the hospitals' internal labs for their help in estimating biomarkers levels. There was no specific funding for this specific study.

AUTHOR CONTRIBUTIONS

HTA and DSA recruited the patients and collected blood samples. HTA and HAH measured the serum biomarkers. MM performed the statistical analysis. All authors contributed to the drafting and editing of the paper, and all authors approved the final version of the paper.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL

The research was approved by the University of Kufa's institutional ethics board (8241/2021) and the Najaf Health Directorate-Training and Human Development Center (Document No.18378/ 2021). The study was conducted according to Iraq and international ethics and privacy laws and was conducted ethically following the World Medical Association Declaration of Helsinki. Furthermore, our IRB follows the International Guideline for Human Research protection as required by the Declaration of Helsinki, The Belmont Report, CIOMS Guideline and the International Conference on Harmonization in Good Clinical Practice (ICH-GCP).

CONSENT FOR PUBLICATION

All participants gave written informed consent before participating in this study.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-022-01836-9>.

Correspondence and requests for materials should be addressed to Michael Maes.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.